Your shopping cart is currently empty

SBP-7455 potently inhibited ULK1/2 enzymatic activity in vitro and in cells, reduced the viability of TNBC cells and had oral bioavailability in mice.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $59 | In Stock | In Stock | |
| 5 mg | $121 | In Stock | In Stock | |
| 10 mg | $202 | In Stock | In Stock | |
| 25 mg | $364 | In Stock | In Stock | |
| 50 mg | $594 | In Stock | In Stock | |
| 100 mg | $745 | In Stock | In Stock |
| Description | SBP-7455 potently inhibited ULK1/2 enzymatic activity in vitro and in cells, reduced the viability of TNBC cells and had oral bioavailability in mice. |
| Targets&IC50 | Autophagy:0.3 μM, ULK1:13 nM, ULK2:476 nM |
| In vitro | SBP-7455 treatment inhibits cell growth with an IC50 of 0.3 μM for MDA-MB-468 cells. SBP-7455 inhibits starvation-induced autophagic flux in TNBC cells that are dependent on autophagy for survival[1]. |
| In vivo | To evaluate the PD profile and in vivo target engagement, mice were dosed with SBP-7455 (10 mg/kg) or vehicle by oral gavage, and liver samples were collected after 2 h.Based on the PK and PD profiles, our data show that SBP-7455 is an efficacious tool that can be used to modulate autophagy in vivop[1]. |
| Molecular Weight | 354.33 |
| Formula | C16H17F3N4O2 |
| Cas No. | 1884222-74-5 |
| Smiles | COc1ccc(Nc2ncc(c(NC3CC3)n2)C(F)(F)F)cc1OC |
| Relative Density. | 1.405 g/cm3 (Predicted) |
| Storage | store at low temperature | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 120 mg/mL (338.67 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (11.29 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.